Carolina Porras - Publications

Development of HPV 35 serology assays for assessment of immune responses to HPV 35 after infection and vaccination.

Journal: Human vaccines & immunotherapeutics

Published: January 27, 2026

Hybrid immunity provides stronger protection against SARS-CoV-2 infection than vaccination alone: Evidence from a population-based active monitoring study.

Journal: Vaccine

Published: January 09, 2026

Noninferiority of One HPV Vaccine Dose to Two Doses.

Journal: The New England journal of medicine

Published: December 03, 2025

Resilience of Biobanks in Latin America During the COVID-19 Pandemic: Lessons from Costa Rica.

Journal: Biopreservation and biobanking

Published: September 02, 2025

Association of Levonorgestrel-Containing Emergency Contraceptive Pills with Breast Cancer in Premenopausal Latin American Women: The PRECAMA Study.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: August 08, 2025

SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.

Journal: PloS one

Published: April 24, 2025

Validation of TypeSeq2, a Next-Generation-Based Sequencing Assay for the Detection of 46 Human Papillomavirus Genotypes, at the US National Cancer Institute and Costa Rica Laboratories.

Journal: The Journal of infectious diseases

Published: March 20, 2025

Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.

Journal: International journal of cancer

Published: December 23, 2024

Descriptive epidemiology of gastric cancer in Costa Rica from 1990 to 2022 and projection of deaths to 2050: a population-based study.

Journal: Lancet regional health. Americas

Published: December 16, 2024

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial.

Journal: The Lancet. Infectious diseases

Published: October 08, 2024

Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).

Journal: Vaccine

Published: August 21, 2024

Trends in psychological distress during and after the COVID-19 pandemic: Findings from a population-based Costa Rican cohort study.

Journal: Public health

Published: August 09, 2024